fig1

Porcupine inhibition: a novel disease-modifier target in arrhythmogenic cardiomyopathy

Figure 1. Canonical Wnt pathway in a cardiomyocyte of a Myh6-Cre-DspW/F mouse model. (1) Upon activation, β-catenin translocates to the nucleus. Its interaction with TCF/LEF activates the expression of a myriad of genes involved in cardiac fibrosis. (2) The inactivation of the canonical Wnt pathway leads β-catenin to proteasomal degradation. (3) Porcupine, a post-translational enzyme localized to the endoplasmic reticulum, palmitoylates Wnt ligands for subsequent transmembrane transport and secretion to the extracellular space. WNT974, a Porcupine inhibitor, blocks this key step thereby suppressing the canonical pathway central to the pathogenesis of arrhythmogenic cardiomyopathy.

The Journal of Cardiovascular Aging
ISSN 2768-5993 (Online)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/